Every 8-K that Biodesix, Inc. (BDSX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BDSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDSX filings page.
Biodesix, Inc. reported second-quarter 2026 results with total revenue of $26.9 million, a 34% year-over-year increase. Diagnostic Testing revenue was $25.4 million, up 42%, driven by 20,900 tests, a 38% volume increase and higher average revenue per test. Development Services revenue was $1.5 million, reflecting project timing.
Gross margin reached 82%, a 200-basis-point improvement. Operating expenses excluding direct costs were $27.4 million, up 7%. Net loss narrowed to $7.3 million, a 37% improvement, and Adjusted EBITDA loss improved to $3.2 million, a 56% improvement. Cash and cash equivalents were $30.0 million. Total assets were $95.3 million and stockholders’ equity improved to $9.1 million, up from a deficit at year-end 2025, while long-term notes payable were $46.8 million. Full-year 2026 revenue guidance remains $108–114 million, with the midpoint implying about 25% growth and maintaining gross margin of roughly 80% while progressing toward Adjusted EBITDA profitability.
Biodesix, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected two Class III directors to serve until the 2029 annual meeting, approved on a non-binding advisory basis the compensation of named executive officers, and chose to hold say-on-pay votes every year.
They also ratified the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. A total of 10,107,219 shares of common stock were entitled to vote as of the March 23, 2026 record date.
Biodesix, Inc. reported strong first quarter 2026 results with total revenue of $25.6 million, up 42% year over year, driven by growth in both Diagnostic Testing and Development Services. Diagnostic Testing revenue reached $22.3 million on 29% higher test volumes and better average revenue per test, while Development Services revenue nearly doubled to $3.3 million.
Gross margin was 84% in the quarter, or 82% excluding a one‑time $0.4 million tax recovery, about a 300‑basis‑point improvement from a year earlier. Operating expenses rose 18% to $27.6 million as the company invested in sales, marketing, and G&A, including $1.1 million of share-based compensation. Net loss improved to $7.8 million from $11.1 million, and Adjusted EBITDA loss narrowed to $4.1 million from $6.2 million.
Cash and cash equivalents increased to $25.6 million from $19.0 million at year end, helped by $16.8 million of at-the-market net proceeds. Reflecting the strong start to the year, Biodesix raised its 2026 total revenue outlook to $108–114 million, with the midpoint implying about 25% growth over 2025, and continues to target progress toward Adjusted EBITDA profitability.
Biodesix reported strong fourth-quarter and full-year 2025 results, highlighted by rapid growth and improving profitability metrics. Q4 revenue reached $28.8 million, up 41%, with gross margin expanding to 83%. For 2025, total revenue was $88.5 million and gross margin was 81%, reflecting operating scale in its lung-focused diagnostics and development services businesses.
Net loss narrowed to $4.0 million in Q4 and $35.3 million for 2025, while Adjusted EBITDA turned positive at $0.5 million in Q4 and improved to a $17.5 million loss for the year. The company ended 2025 with $19.0 million in cash and subsequently raised an additional $14.7 million and extended its senior term loan maturity to November 2028. For 2026, Biodesix guides revenue between $106 million and $112 million, with the midpoint implying about 23% growth and continued progress toward sustained Adjusted EBITDA profitability.
Biodesix, Inc. filed an amended current report to change how its recent earnings press release is treated under securities law. The company previously issued a press release with certain preliminary and unaudited financial results for the fourth quarter and year ended December 31, 2025. Through this amendment, Biodesix is recharacterizing that press release, which is attached as Exhibit 99.1, so that it is considered "filed" rather than "furnished" under the Exchange Act. The company states that no other changes have been made beyond this filing status update.
Biodesix, Inc. furnished an 8-K announcing its financial and operating results for the third quarter ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1 and incorporated by reference as stated. The company noted the information is furnished, not filed, under the Exchange Act.
Biodesix, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Global Market. On September 26, 2025, Nasdaq notified the company that its common stock once again meets the rule that requires a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. This notice closes the earlier deficiency matter that began when the stock traded below $1.00 for 30 consecutive business days.
Biodesix, Inc. (BDSX) completed a one-for-twenty reverse stock split of its common stock effective at 12:01 a.m. ET on September 15, 2025, and began trading on a split-adjusted basis under a new CUSIP (09075X207). The reverse split was authorized by stockholders at the May 20, 2025 annual meeting permitting a split ratio between 1:2 and 1:20; the Board selected the 1-for-20 ratio on September 4, 2025 and filed the required amendment with the Delaware Secretary of State.
Separately, Biodesix filed a Certificate of Elimination with the Delaware Secretary of State effective September 12, 2025 removing the provisions of the Certificate of Designations for the previously issued Series A Non-Voting Convertible Preferred Stock. The filings referenced include a Certificate of Amendment to the charter and the Certificate of Elimination; the document is signed by the CFO and includes embedded Inline XBRL cover page data.
Biodesix, Inc. disclosed that its board of directors approved a one-for-twenty reverse stock split of its common stock. The reverse split is expected to become effective on September 15, 2025 at 12:01 a.m. Eastern Time, and the shares are expected to begin trading on a split-adjusted basis at market open that same day.
At the effective time, every 20 shares of Biodesix common stock issued and outstanding will automatically convert into 1 share of common stock. Stockholders will receive cash in lieu of fractional shares, based on the Nasdaq closing price on the last trading day before the effective date. Biodesix will make proportionate adjustments to shares underlying outstanding equity awards, shares issuable under equity incentive plans and other agreements, and to the number of shares and exercise prices of its outstanding warrants to reflect the reverse split.